I-Mab - ADR

NASDAQ:IMAB   1:01:41 PM EDT
4.73
+0.12 (+2.60%)
Earnings Announcements

I-Mab Reports Financial Results For Six Months Ended June 30, 2022

Published: 08/30/2022 10:17 GMT
I-Mab - ADR (IMAB) - I-mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022.
I-mab - Lemzoparlimab is on Track for Phase 3 Study for 1l Mds.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $25 Million
Next Quarter EPS Guidance is expected to be -$0.92

More details on our Analysts Page.